ArticleApplied biochemistry and biotechnology2025
Eco-friendly Synthesis of Iron Oxide Nanoparticles Using Parietaria alsinifolia Extracts and Evaluation of Biological Applications.
Article in Applied biochemistry and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Biogenic synthesis and characterization of antimicrobial, anti-inflammatory, antioxidant, and biocompatible iron oxide nanoparticles (FeONPs) using Arthrospira sp. Extract.Discover nano · 2026Article
- Green-synthesized cardamom-modified iron oxide nanoparticles with potent antibacterial, antioxidant, anti-inflammatory, and anticancer activities.RSC advances · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The current research was conducted to synthesize Parietaria alsinifolia-mediated iron oxide nanoparticles (P.A@FeONPs) using the green and eco-friendly protocol. The biosynthesized P.A@FeONPs were characterized using various approaches like UVs, FTIR, SEM, EDX, and DLS. The mean crystallite size was calculated to be ~ 21.48 nm using the Debye-Scherrer equation. Further, various in vitro biological assays were performed to analyze the therapeutic potentials of FeONPs. 2,2-Diphenyl-1-picrylhydrazy (DPPH) antioxidant activity was performed to reveal the DPPH radical scavenging potential of P.A@FeONPs and was calculated as 72%. Similarly, the total reducing power was determined as 65.45 ± 1.77%. In addition, P.A@FeONPs exhibited a significant total antioxidant capacity of 87 ± 4.8%. Antibacterial and antifungal assays were performed using the disc diffusion method. Among the different bacterial strains accession (EFB-10-2023 M.B), Rhodococcus jostii has shown the highest zone of inhibition (23.9 mm at 1000 μg/mL), while Escherichia coli displayed a 22.65 mm zone of inhibition at (1000 μg/mL). Similarly, Aspergillus niger exhibited a substantial zone of inhibition (28.75 mm). A brine shrimp cytotoxicity assay revealed the cytotoxicity potential (LC
Indexed as
Identifiers
39752127What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.